Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$1.83 - $3.84 $4 Million - $8.4 Million
2,186,960 New
2,186,960 $4.22 Million
Q3 2020

Nov 03, 2020

BUY
$15.7 - $20.84 $6.68 Million - $8.87 Million
425,726 New
425,726 $7.88 Million

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $90.1M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Bpifrance Sa Portfolio

Follow Bpifrance Sa and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bpifrance Sa, based on Form 13F filings with the SEC.

News

Stay updated on Bpifrance Sa with notifications on news.